These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20870604)

  • 1. [Possibilities of genetic screening at the National Oncology Institute].
    Magy Onkol; 2010 Sep; 54(3):269. PubMed ID: 20870604
    [No Abstract]   [Full Text] [Related]  

  • 2. EPCAM deletions, Lynch syndrome, and cancer risk.
    Lynch HT; Lynch JF; Snyder CL; Riegert-Johnson D
    Lancet Oncol; 2011 Jan; 12(1):5-6. PubMed ID: 21195320
    [No Abstract]   [Full Text] [Related]  

  • 3. Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion.
    Grandval P; Baert-Desurmont S; Bonnet F; Bronner M; Buisine MP; Colas C; Noguchi T; North MO; Rey JM; Tinat J; Toulas C; Olschwang S
    Clin Genet; 2012 Jul; 82(1):97-9. PubMed ID: 22243433
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cancer genetics: estimation of the needs of the population in France for the next ten years].
    Bonaïti-Pellié C; Andrieu N; Arveux P; Bonadona V; Buecher B; Delpech M; Jolly D; Julian-Reynier C; Luporsi E; Noguès C; Nowak F; Olschwang S; Orsi F; Pujol P; Saurin JC; Sinilnikova O; Stoppa-Lyonnet D; Thépot F
    Bull Cancer; 2009 Sep; 96(9):875-900. PubMed ID: 19751997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.
    Hall MJ; Obeid EI; Schwartz SC; Mantia-Smaldone G; Forman AD; Daly MB
    Gynecol Oncol; 2016 Mar; 140(3):565-74. PubMed ID: 26812021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer genetics and reproduction.
    Hanson H; Hodgson S
    Best Pract Res Clin Obstet Gynaecol; 2010 Feb; 24(1):3-18. PubMed ID: 19864186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome.
    Howarth DR; Lum SS; Esquivel P; Garberoglio CA; Senthil M; Solomon NL
    Am Surg; 2015 Oct; 81(10):941-4. PubMed ID: 26463285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human embryos in Britain may be screened for cancer risk.
    Weiss R
    Washington Post; 2006 May; ():A12. PubMed ID: 16856290
    [No Abstract]   [Full Text] [Related]  

  • 10. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing by cancer site: ovary.
    Weissman SM; Weiss SM; Newlin AC
    Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time?
    De Silva DL; James PA; Mann GB; Lindeman GJ
    Med J Aust; 2021 Nov; 215(10):449-453. PubMed ID: 34676562
    [No Abstract]   [Full Text] [Related]  

  • 13. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; van Gool AR; Klijn JG; Tibben A
    Clin Genet; 2007 Jan; 71(1):35-42. PubMed ID: 17204044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.
    Kovacs ME; Papp J; Szentirmay Z; Otto S; Olah E
    Hum Mutat; 2009 Feb; 30(2):197-203. PubMed ID: 19177550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlations between the patient's genotype and the course of the disease in hereditary cancer diseases].
    Bisgaard ML
    Ugeskr Laeger; 2006 Jun; 168(24):2341-4. PubMed ID: 16822416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Professional challenges in cancer genetic testing: who is the patient?
    Chan-Smutko G; Patel D; Shannon KM; Ryan PD
    Oncologist; 2008 Mar; 13(3):232-8. PubMed ID: 18378533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of breast cancer: contribution of BRCA1/2 genes alterations to hereditary predisposition.
    Branković-Magić M; Dobricić J; Krivokuća A
    Vojnosanit Pregl; 2012 Aug; 69(8):700-6. PubMed ID: 22924267
    [No Abstract]   [Full Text] [Related]  

  • 20. US panel rejects routine use of BRCA cancer screening in women.
    McCarthy M
    BMJ; 2013 Apr; 346():f2160. PubMed ID: 23558348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.